Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cancer Res. 2017 Dec 12;78(4):1110–1122. doi: 10.1158/0008-5472.CAN-17-2686

Figure 5. Functional validation of novel ESR1 p.A569S mutation demonstrates modest estradiol sensitivity and increased tamoxifen agonist activity.

Figure 5

A. Summary of ESR1 mutations detected in Patient #2 from tissue, CTC-DNA, and cfDNA in schematic representation of the encoded ERα with the LBD and F domains indicated; B. MCF-7 ESR1 A569S are more sensitive to estradiol after 5 days when assessed by crystal violet assay. Inset table indicates EC50 of estradiol in pM; C. Tamoxifen has increased agonist activity in MCF-7 cells over-expressing ER-A569S. Inset table indicates maximal growth at 100nM tamoxifen. Assays were performed in triplicates with P-values error bars (standard error) indicated.

HHS Vulnerability Disclosure